INTERCEPT PHARMACEUTICALS, INC. Insider Trading for August 2014
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in INTERCEPT PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in INTERCEPT PHARMACEUTICALS, INC. for August 2014.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 29 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 8.67 | 10,000 | 86,667 | 30,131 | |
| Aug 29 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 296.14 | 700 | 207,295 | 14,253 | 15 K to 14.3 K (-4.68 %) |
| Aug 29 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 295.61 | 1,200 | 354,732 | 14,953 | 16.2 K to 15 K (-7.43 %) |
| Aug 29 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 293.89 | 4,250 | 1,249,025 | 16,153 | 20.4 K to 16.2 K (-20.83 %) |
| Aug 29 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 293.05 | 3,850 | 1,128,233 | 20,403 | 24.3 K to 20.4 K (-15.87 %) |
| Aug 29 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 8.67 | 10,000 | 86,667 | 24,253 | 14.3 K to 24.3 K (+70.16 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Sell | S | 295.13 | 1,000 | 295,125 | 1,465 | 2.5 K to 1.5 K (-40.57 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Sell | S | 295.04 | 1,433 | 422,794 | 2,465 | 3.9 K to 2.5 K (-36.76 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 302.34 | 400 | 120,936 | 1,485,324 | 1.5 M to 1.5 M (-0.03 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 301.36 | 5,400 | 1,627,344 | 1,485,724 | 1.5 M to 1.5 M (-0.36 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 300.11 | 45,058 | 13,522,356 | 1,491,124 | 1.5 M to 1.5 M (-2.93 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 299.13 | 10,400 | 3,110,952 | 1,536,182 | 1.5 M to 1.5 M (-0.67 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 297.26 | 1,990 | 591,547 | 1,546,582 | 1.5 M to 1.5 M (-0.13 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 296.59 | 10,010 | 2,968,866 | 1,548,572 | 1.6 M to 1.5 M (-0.64 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 295.52 | 25,442 | 7,518,620 | 1,558,582 | 1.6 M to 1.6 M (-1.61 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 294.67 | 12,558 | 3,700,466 | 1,584,024 | 1.6 M to 1.6 M (-0.79 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 308.13 | 350 | 107,844 | 1,596,582 | 1.6 M to 1.6 M (-0.02 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 307.06 | 14,640 | 4,495,314 | 1,596,932 | 1.6 M to 1.6 M (-0.91 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 306.23 | 525 | 160,772 | 1,611,572 | 1.6 M to 1.6 M (-0.03 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 305.14 | 1,732 | 528,501 | 1,612,097 | 1.6 M to 1.6 M (-0.11 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 303.77 | 1,193 | 362,394 | 1,613,829 | 1.6 M to 1.6 M (-0.07 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 302.55 | 1,100 | 332,806 | 1,615,022 | 1.6 M to 1.6 M (-0.07 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 301.42 | 1,710 | 515,426 | 1,616,122 | 1.6 M to 1.6 M (-0.11 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 300.21 | 3,985 | 1,196,329 | 1,617,832 | 1.6 M to 1.6 M (-0.25 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 298.61 | 100 | 29,861 | 1,621,817 | 1.6 M to 1.6 M (-0.01 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 297.76 | 9,985 | 2,973,134 | 1,621,917 | 1.6 M to 1.6 M (-0.61 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 296.86 | 6,192 | 1,838,139 | 1,631,902 | 1.6 M to 1.6 M (-0.38 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 296.21 | 7,062 | 2,091,814 | 1,638,094 | 1.6 M to 1.6 M (-0.43 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 294.96 | 3,254 | 959,800 | 1,645,156 | 1.6 M to 1.6 M (-0.20 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 293.85 | 4,468 | 1,312,908 | 1,648,410 | 1.7 M to 1.6 M (-0.27 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Sell | S | 292.70 | 3,704 | 1,084,165 | 1,652,878 | 1.7 M to 1.7 M (-0.22 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 302.34 | 400 | 120,936 | 1,485,324 | 1.5 M to 1.5 M (-0.03 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 301.36 | 5,400 | 1,627,344 | 1,485,724 | 1.5 M to 1.5 M (-0.36 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 300.11 | 45,058 | 13,522,356 | 1,491,124 | 1.5 M to 1.5 M (-2.93 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 299.13 | 10,400 | 3,110,952 | 1,536,182 | 1.5 M to 1.5 M (-0.67 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 297.26 | 1,990 | 591,547 | 1,546,582 | 1.5 M to 1.5 M (-0.13 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 296.59 | 10,010 | 2,968,866 | 1,548,572 | 1.6 M to 1.5 M (-0.64 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 295.52 | 25,442 | 7,518,620 | 1,558,582 | 1.6 M to 1.6 M (-1.61 %) |
| Aug 27 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 294.67 | 12,558 | 3,700,466 | 1,584,024 | 1.6 M to 1.6 M (-0.79 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 308.13 | 350 | 107,844 | 1,596,582 | 1.6 M to 1.6 M (-0.02 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 307.06 | 14,640 | 4,495,314 | 1,596,932 | 1.6 M to 1.6 M (-0.91 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 306.23 | 525 | 160,772 | 1,611,572 | 1.6 M to 1.6 M (-0.03 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 305.14 | 1,732 | 528,501 | 1,612,097 | 1.6 M to 1.6 M (-0.11 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 303.77 | 1,193 | 362,394 | 1,613,829 | 1.6 M to 1.6 M (-0.07 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 302.55 | 1,100 | 332,806 | 1,615,022 | 1.6 M to 1.6 M (-0.07 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 301.42 | 1,710 | 515,426 | 1,616,122 | 1.6 M to 1.6 M (-0.11 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 300.21 | 3,985 | 1,196,329 | 1,617,832 | 1.6 M to 1.6 M (-0.25 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 298.61 | 100 | 29,861 | 1,621,817 | 1.6 M to 1.6 M (-0.01 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 297.76 | 9,985 | 2,973,134 | 1,621,917 | 1.6 M to 1.6 M (-0.61 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 296.86 | 6,192 | 1,838,139 | 1,631,902 | 1.6 M to 1.6 M (-0.38 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 296.21 | 7,062 | 2,091,814 | 1,638,094 | 1.6 M to 1.6 M (-0.43 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 294.96 | 3,254 | 959,800 | 1,645,156 | 1.6 M to 1.6 M (-0.20 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 293.85 | 4,468 | 1,312,908 | 1,648,410 | 1.7 M to 1.6 M (-0.27 %) |
| Aug 18 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Sell | S | 292.70 | 3,704 | 1,084,165 | 1,652,878 | 1.7 M to 1.7 M (-0.22 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Option Exercise | M | 10.40 | 4,000 | 41,600 | 22,703 | |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 292.16 | 4,000 | 1,168,656 | 14,253 | 18.3 K to 14.3 K (-21.91 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Sell | S | 288.00 | 774 | 222,912 | 18,253 | 19 K to 18.3 K (-4.07 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Shapiro David | CMO and EVP - Devel ... | Buy | M | 10.40 | 4,000 | 41,600 | 19,027 | 15 K to 19 K (+26.62 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Option Exercise | M | 37.69 | 8,124 | 306,194 | 101,875 | |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 346.68 | 224 | 77,656 | 1,410 | 1.6 K to 1.4 K (-13.71 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 344.73 | 500 | 172,366 | 1,634 | 2.1 K to 1.6 K (-23.43 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 343.80 | 800 | 275,039 | 2,134 | 2.9 K to 2.1 K (-27.27 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 342.05 | 300 | 102,614 | 2,934 | 3.2 K to 2.9 K (-9.28 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 341.21 | 300 | 102,362 | 3,234 | 3.5 K to 3.2 K (-8.49 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 337.17 | 100 | 33,717 | 3,534 | 3.6 K to 3.5 K (-2.75 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 336.47 | 200 | 67,293 | 3,634 | 3.8 K to 3.6 K (-5.22 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 335.02 | 100 | 33,502 | 3,834 | 3.9 K to 3.8 K (-2.54 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 331.92 | 200 | 66,384 | 3,934 | 4.1 K to 3.9 K (-4.84 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 330.91 | 206 | 68,167 | 4,134 | 4.3 K to 4.1 K (-4.75 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 329.59 | 594 | 195,777 | 4,340 | 4.9 K to 4.3 K (-12.04 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 327.89 | 300 | 98,366 | 4,934 | 5.2 K to 4.9 K (-5.73 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 326.03 | 100 | 32,603 | 5,234 | 5.3 K to 5.2 K (-1.87 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 322.92 | 100 | 32,292 | 5,334 | 5.4 K to 5.3 K (-1.84 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 321.44 | 200 | 64,288 | 5,434 | 5.6 K to 5.4 K (-3.55 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 319.47 | 400 | 127,787 | 5,634 | 6 K to 5.6 K (-6.63 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 317.71 | 400 | 127,082 | 6,034 | 6.4 K to 6 K (-6.22 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 316.62 | 200 | 63,324 | 6,434 | 6.6 K to 6.4 K (-3.01 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 314.93 | 600 | 188,955 | 6,634 | 7.2 K to 6.6 K (-8.29 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 313.84 | 800 | 251,072 | 7,234 | 8 K to 7.2 K (-9.96 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 312.78 | 200 | 62,555 | 8,034 | 8.2 K to 8 K (-2.43 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 311.89 | 500 | 155,943 | 8,234 | 8.7 K to 8.2 K (-5.72 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 310.11 | 500 | 155,052 | 8,734 | 9.2 K to 8.7 K (-5.41 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 306.91 | 100 | 30,691 | 9,234 | 9.3 K to 9.2 K (-1.07 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Sell | S | 305.39 | 200 | 61,077 | 9,334 | 9.5 K to 9.3 K (-2.10 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Regan Daniel Paul | Chief Commercial Of ... | Buy | M | 37.69 | 8,124 | 306,194 | 9,534 | 1.4 K to 9.5 K (+576.17 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Option Exercise | M | 21.50 | 316 | 6,794 | 11,882 | |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 345.62 | 316 | 109,216 | 2,166 | 2.5 K to 2.2 K (-12.73 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Buy | M | 21.50 | 316 | 6,794 | 2,482 | 2.2 K to 2.5 K (+14.59 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Option Exercise | M | 8.67 | 11,038 | 95,663 | 8,000 | |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 346.52 | 138 | 47,819 | 8,113 | 8.3 K to 8.1 K (-1.67 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 345.13 | 300 | 103,540 | 8,251 | 8.6 K to 8.3 K (-3.51 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 344.00 | 400 | 137,599 | 8,551 | 9 K to 8.6 K (-4.47 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 342.69 | 203 | 69,566 | 8,951 | 9.2 K to 9 K (-2.22 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 341.90 | 497 | 169,926 | 9,154 | 9.7 K to 9.2 K (-5.15 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 340.28 | 300 | 102,083 | 9,651 | 10 K to 9.7 K (-3.01 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 337.30 | 200 | 67,460 | 9,951 | 10.2 K to 10 K (-1.97 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 335.14 | 100 | 33,514 | 10,151 | 10.3 K to 10.2 K (-0.98 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 332.05 | 100 | 33,205 | 10,251 | 10.4 K to 10.3 K (-0.97 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 331.70 | 300 | 99,510 | 10,351 | 10.7 K to 10.4 K (-2.82 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 329.95 | 500 | 164,974 | 10,651 | 11.2 K to 10.7 K (-4.48 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 328.20 | 400 | 131,278 | 11,151 | 11.6 K to 11.2 K (-3.46 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 327.49 | 200 | 65,498 | 11,551 | 11.8 K to 11.6 K (-1.70 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 325.66 | 200 | 65,131 | 11,751 | 12 K to 11.8 K (-1.67 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 322.03 | 100 | 32,203 | 11,951 | 12.1 K to 12 K (-0.83 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 321.00 | 100 | 32,100 | 12,051 | 12.2 K to 12.1 K (-0.82 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 320.21 | 200 | 64,041 | 12,151 | 12.4 K to 12.2 K (-1.62 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 319.09 | 300 | 95,726 | 12,351 | 12.7 K to 12.4 K (-2.37 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 317.70 | 500 | 158,848 | 12,651 | 13.2 K to 12.7 K (-3.80 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 316.63 | 900 | 284,971 | 13,151 | 14.1 K to 13.2 K (-6.41 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 315.01 | 1,000 | 315,009 | 14,051 | 15.1 K to 14.1 K (-6.64 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 313.71 | 1,100 | 345,076 | 15,051 | 16.2 K to 15.1 K (-6.81 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 312.41 | 1,000 | 312,411 | 16,151 | 17.2 K to 16.2 K (-5.83 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 311.40 | 600 | 186,840 | 17,151 | 17.8 K to 17.2 K (-3.38 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 310.20 | 600 | 186,122 | 17,751 | 18.4 K to 17.8 K (-3.27 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 307.58 | 400 | 123,033 | 18,351 | 18.8 K to 18.4 K (-2.13 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Sell | S | 306.49 | 400 | 122,597 | 18,751 | 19.2 K to 18.8 K (-2.09 %) |
| Aug 15 2014 | ICPT | INTERCEPT PHARMACE ... | Adorini Luciano | Chief Scientific Of ... | Buy | M | 8.67 | 11,038 | 95,663 | 19,151 | 8.1 K to 19.2 K (+136.05 %) |
| Aug 12 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Option Exercise | M | 0.00 | 324 | 0 | 0 | |
| Aug 12 2014 | ICPT | INTERCEPT PHARMACE ... | SILVERSTEIN JONATHAN | Director | Buy | M | 0.00 | 324 | 0 | 609 | 285 to 609 (+113.68 %) |
| Aug 12 2014 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Option Exercise | M | 0.00 | 324 | 0 | 0 | |
| Aug 12 2014 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Sell | S | 239.49 | 324 | 77,595 | 8,803 | 9.1 K to 8.8 K (-3.55 %) |
| Aug 12 2014 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Buy | M | 0.00 | 324 | 0 | 9,127 | 8.8 K to 9.1 K (+3.68 %) |
| Aug 12 2014 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Option Exercise | M | 0.00 | 368 | 0 | 0 | |
| Aug 12 2014 | ICPT | INTERCEPT PHARMACE ... | WILLIAMS NICOLE | Director | Buy | M | 0.00 | 368 | 0 | 3,898 | 3.5 K to 3.9 K (+10.42 %) |
| Aug 12 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Option Exercise | M | 21.50 | 391 | 8,407 | 12,198 | |
| Aug 12 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Option Exercise | M | 0.00 | 324 | 0 | 0 | |
| Aug 12 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 239.49 | 391 | 93,641 | 2,166 | 2.6 K to 2.2 K (-15.29 %) |
| Aug 12 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Buy | M | 21.50 | 391 | 8,407 | 2,557 | 2.2 K to 2.6 K (+18.05 %) |
| Aug 12 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 238.28 | 1 | 238 | 2,166 | 2.2 K to 2.2 K (-0.05 %) |
| Aug 12 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 238.26 | 93 | 22,158 | 2,167 | 2.3 K to 2.2 K (-4.12 %) |
| Aug 12 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 238.25 | 6 | 1,430 | 2,260 | 2.3 K to 2.3 K (-0.26 %) |
| Aug 12 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Sell | S | 234.71 | 64 | 15,021 | 2,266 | 2.3 K to 2.3 K (-2.75 %) |
| Aug 12 2014 | ICPT | INTERCEPT PHARMACE ... | VEITINGER KLAUS R DR | Director | Buy | M | 0.00 | 324 | 0 | 2,330 | 2 K to 2.3 K (+16.15 %) |
| Aug 11 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Option Exercise | M | 0.00 | 324 | 0 | 0 | |
| Aug 11 2014 | ICPT | INTERCEPT PHARMACE ... | ORBIMED ADVISORS LLC | Director | Buy | M | 0.00 | 324 | 0 | 1,656,582 | 1.7 M to 1.7 M (+0.02 %) |
| Aug 06 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Option Exercise | M | 8.67 | 10,000 | 86,667 | 176,628 | |
| Aug 06 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Sell | S | 226.72 | 10,000 | 2,267,198 | 475,042 | 485 K to 475 K (-2.06 %) |
| Aug 06 2014 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | CEO & President | Buy | M | 8.67 | 10,000 | 86,667 | 485,042 | 475 K to 485 K (+2.11 %) |